Literature DB >> 630793

Effect of lithium on plasma chlorpromazine levels.

L Rivera-Calimlim, B Kerzner, F E Karch.   

Abstract

The interaction of lithium and chlorpromazine (CPZ) was studied in healthy volunteers in a randomized crossover study. Each subject ingested two doses of CPZ (100 mg) as the liquid concentrate: (1) without concurrent lithium therapy and (2) after a 7-day treatment with lithium carbonate (900 mg/day). When CPZ was administered with lithium, peak plasma CPZ levels were 40.3% (mean) lower than those without lithium (p = 0.006), and the area under the CPZ plasma concentration time curve was 26.6% smaller (p = 0.08). The time to reach peak plasma CPZ levels was similar in both groups. All subjects slept for 4 to 6 hr after oral CPZ and had a maximum fall in both systolic (8 to 32 mg Hg) and diastolic (5 to 23 mg Hg) blood pressure at the time of peak plasma CPZ concentration. This lithium-CPZ interaction may explain the low plasma CPZ levels reported previously in psychiatric patients taking both lithium and CPZ.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 630793     DOI: 10.1002/cpt1978234451

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Psychotherapeutic drugs: important adverse reactions and interactions.

Authors:  G D Burrows; T R Norman
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

2.  Ventricular fibrillation due to lithium withdrawal--an interaction with chlorpromazine?

Authors:  R N Stevenson; C Blanshard; D L Patterson
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

Review 3.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.